Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer Health Care has commenced the enrollment of patients for an international Phase III trial to study its investigational compound BAY94-9027, used to treat hemophilia A.
Subscribe to our email newsletter
The multicenter, multinational, partially randomized, open-label trial includes 120 to 140 previously treated subjects (PTP).
The PROTECT VIII (PROphylaxis in hemophilia A patienTs via directly pEgylated long-aCTing rFVIII) trial aims to investigate whether BAY94-9027, a recombinant human factor VIII (rFVIII), can enhance the period of protection from bleeds and with less infusions when administered prophylactically.
Bayer HealthCare global development Head Kemal Malik said the company has more than 20 years of research and clinical experience in hemophilia, and continues to invest in innovative ways to advance patient care, such as the development of BAY94-9027.
"A longer-acting rFVIII product may result in significant benefit in long-term outcomes and quality of life improvements for people with hemophilia A," Malik added.